ClinicalTrials.gg
CompletedNCT03968848Updated Sep 10, 2021Results posted

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

A Phase 1 interventional study of acalabrutinib in Hepatic Impairment, Hepatic Insufficiency and Healthy Subjects, sponsored by Acerta Pharma BV. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-10.

Sponsored by Acerta Pharma BV (part of AstraZeneca) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2018, registered May 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 52 studies in Hepatic Insufficiency with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Hepatic Insufficiency · United States.

Enrollment
38th of 48
16 · median 28
Started
2018
with 1 other
Phase 1
42 of 52
3 open now
Registered
32nd of 52
by date
Lead sponsor
2 of 52
Acerta Pharma BV

Among the 52 studies in Hepatic Insufficiency with a site in United States, this one is the 38th largest by enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2018, is one of 42 in phase 1, and was the 32nd registered.

Hepatic Insufficiency

113 studies on the registry are indexed under Hepatic Insufficiency; 15 are open to participants now.

Browse Hepatic Insufficiency studies →

Open to participants now

3 of the 52 studies in Hepatic Insufficiency with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Hepatic Insufficiency studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Hepatic Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This study is investigate the influence of severe hepatic impairment on the pharmacokinetics of acalabrutinib and its metabolite.

03

Conditions studied

  • Hepatic Impairment
  • Hepatic Insufficiency
  • Healthy Subjects

Browse trials for

Keywords

  • Hepatic
  • Acalabrutinib
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women must be of non childbearing status
  • Understands the study procedures in the ICF and be willing and able to comply with the protocol.
  • Willingness and ability to swallow study drug capsule.
  • Adult men or women, 18 to 75 years of age

Hepatic-Impaired Subjects Only:

  • Subject has a diagnosis of chronic, stable HI.
  • Subject's score on the scale must range from 10 to 15 at screening.

Exclusion criteria

Exclusion Criteria

  • History or presence of or unstable medical or psychiatric condition or disease in the opinion of the PI.
  • Dosed in another clinical trial within 28 days before dosing of study drug and throughout the current study.
  • History or presence of drug abuse within 2 years before screening.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Subjects with Severe Hepatic Impairment

    Subjects with severe hepatic impairment (score of 10 to 15 on the Child-Pugh scale) will be administrated a 50-mg single oral dose of acalabrutinib.

    Drug: acalabrutinib

  • Experimental
    Matched-Control Subjects

    Subjects with normal hepatic function will be administrated a 50-mg single oral dose of acalabrutinib.

    Drug: acalabrutinib

Interventions

  • A 50-mg single oral dose of acalabrutinib will be administered.

06

What researchers measure

Primary outcomes

  1. Plasma Acalabrutinib PK Parameters

    Area Under the Concentration-Time Curve

    Time frame: Severe HI: pre-dose, and 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36, 48, 60, 72 hrs post-dose. Normal HI: pre-dose, and 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 hrs post-dose.

  2. Maximum Plasma Acalabrutinib Concentration

    Maximum Cmax

    Time frame: Severe HI: pre-dose, and 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36, 48, 60, 72 hrs post-dose. Normal HI: pre-dose, and 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 hrs post-dose.

07

Results

Posted Sep 10, 2021

Participant flow

Participant flow — Overall Study
MilestoneSevere Hepatic ImpairmentNormal Hepatic Function
Started88
Completed88
Not completed00

Outcome measures

PrimaryPlasma Acalabrutinib PK Parameters

Area Under the Concentration-Time Curve

Time frame:
Severe HI: pre-dose, and 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36, 48, 60, 72 hrs post-dose. Normal HI: pre-dose, and 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 hrs post-dose.
Reported as:
Geometric mean · ng*hr/mL
Plasma Acalabrutinib PK Parameters
ng*hr/mLSevere Hepatic ImpairmentNormal Hepatic Function
AUC0-241167 ± 53.6226.1 ± 55.3
AUC0-last1161 ± 53.9220.0 ± 57.3
AUC0-inf1169 ± 53.8226.5 ± 55.1
PrimaryMaximum Plasma Acalabrutinib Concentration

Maximum Cmax

Time frame:
Severe HI: pre-dose, and 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24, 36, 48, 60, 72 hrs post-dose. Normal HI: pre-dose, and 0.167, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 14, 24 hrs post-dose.
Reported as:
Geometric mean · ng/mL
Maximum Plasma Acalabrutinib Concentration
ng/mLSevere Hepatic ImpairmentNormal Hepatic Function
Maximum Plasma Acalabrutinib Concentration726.0 ± 56.2147.7 ± 116.8

Adverse events

Collected over From first dose of study drug until 30 days post last dose. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Severe Hepatic Impairment0/8 (0%)0/8 (0%)1/8 (12.5%)
Normal Hepatic Function0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent other events
Most frequent other events
EventSevere Hepatic ImpairmentNormal Hepatic Function
HypokalaemiaMetabolism and nutrition disorders1/80/8
HypomagnesaemiaMetabolism and nutrition disorders1/80/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Severe Hepatic ImpairmentNormal Hepatic FunctionTotal
Mean57.6 ± 7.9657.1 ± 4.8857.4 ± 6.39
Sex: Female, Male
Sex: Female, Male(Participants)Severe Hepatic ImpairmentNormal Hepatic FunctionTotal
Female112
Male7714
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Severe Hepatic ImpairmentNormal Hepatic FunctionTotal
Not Hispanic or Latino459
Hispanic or Latino437
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Severe Hepatic ImpairmentNormal Hepatic FunctionTotal
Black or African American011
White8715
Region of Enrollment
Region of Enrollment(Participants)Severe Hepatic ImpairmentNormal Hepatic FunctionTotal
USA8816
08

Study locations

3 sites
  • Research Site
    Miami, Florida 33136, United States
  • Research Site
    Orlando, Florida 32809, United States
  • Research Site
    Knoxville, Tennessee 37920, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Mar 2019, 4 months.

Results were first posted in Sep 2021, 2 years 5 months after primary completion.

Of 38 industry-sponsored phase 1 interventional studies under Hepatic Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 4 months is below that.

Counting every sponsor, half of 41 studies reached it within 8 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2019
First posted
May 30, 2019
StartActual
Nov 12, 2018
Primary completionActual
Mar 13, 2019
CompletionActual
Mar 29, 2019
Results first posted
Sep 10, 2021
Last update
Sep 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03968848
Lead sponsor
Acerta Pharma BV
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
May 30, 2019
Start date
Nov 12, 2018
Primary completion
Mar 13, 2019
Completion
Mar 29, 2019
Results posted
Sep 10, 2021
Last update
Sep 10, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acalabrutinib

Start the discussion